CLINICAL APPLICATION & CRITERIA
Targeted Therapy in China
Targeted therapy uses drugs designed to interfere with specific molecular drivers of cancer growth — mutated proteins, overexpressed receptors, or activated signaling pathways — rather than attacking all rapidly dividing cells. Classes include small-molecule tyrosine kinase inhibitors (TKIs), monoclonal antibodies, antibody-drug conjugates (ADCs), and PARP inhibitors. Treatment requires biomarker testing to identify actionable alterations such as EGFR, ALK, HER2, BRAF, BRCA, or NTRK, enabling a precision medicine approach that often achieves superior responses with fewer systemic side effects than conventional chemotherapy. Resistance is managed through sequential therapy and rational drug combinations.
- Biomarker-Driven Treatment Selection
- Next-Generation Targeted Therapies
- Antibody-Drug Conjugates
- Oral Treatment Options
- Manageable Side Effect Profile
- Resistance Management
CLINICAL INDICATIONS
Key Cancers Treated with Targeted Therapy
WHY CHOOSE US
Why Choose China for Targeted Therapy
China is a global leader in targeted therapy, driven by the uniquely high prevalence of EGFR mutations (40–50% of NSCLC) and other actionable biomarkers in its patient population. Domestic biopharmaceutical companies — Innovent, BeiGene, Hengrui, Chipscreen, and others — have developed multiple world-class targeted drugs, including furmonertinib (third-generation EGFR TKI), zanubrutinib (BTK inhibitor, FDA-approved), and surufatinib, with several reaching global markets through FDA and EMA approvals.
National volume-based procurement and NRDL negotiations have dramatically cut prices: osimertinib, gefitinib, and other once-expensive TKIs are now available at a fraction of Western list prices. The NMPA’s fast-track approval pathways mean novel agents reach Chinese patients rapidly, sometimes before US or European approval. With Grade 3A centers offering NGS molecular diagnostics, MDT molecular tumor boards, and bilingual international patient services, China provides some of the most accessible and advanced targeted oncology care in the world.
HOW IT WORKS
4 Steps to Treatment in China
01. Submit Records Online
02. Pre-Screen & Doctor Match
03. Doctor Consultation
04. Travel to China & Care
PATIENT FAQS
Frequently Asked Questions
CONFIDENTIAL CASE EVALUATION
Start with a Confidential Clinical Case Review
Submit your basic case details below for an initial eligibility review. Our medical team coordinates directly with chief oncologists at top Chinese cancer centers, returning a preliminary assessment and roadmap within 24–48 hours.
✓ Free initial triage • ✓ Direct specialist coordination • ✓ 100% Confidential